Table 2.
Frequency of treatment-related adverse events ≥ 10%
| Adverse event | Toxicity grade |
|||||
|---|---|---|---|---|---|---|
| 1–2 |
3–4 |
Total |
||||
| N | % | N | % | N | % | |
| Fatigue | 24 | 41.4 | 4 | 6.9 | 28 | 48.3 |
| Hypertension | 11 | 19 | 14 | 24.1 | 25 | 43.1 |
| Nausea | 18 | 31 | 0 | 0.0 | 18 | 31.0 |
| Diarrhea | 16 | 27.6 | 0 | 0.0 | 16 | 27.6 |
| Headache | 13 | 22.4 | 0 | 0.0 | 13 | 22.4 |
| Hyperglycemia | 12 | 20.7 | 0 | 0.0 | 12 | 20.7 |
| Anorexia | 12 | 20.7 | 0 | 0.0 | 12 | 20.7 |
| Lymphopenia | 10 | 17.2 | 1 | 1.7 | 11 | 19.0 |
| Hoarseness | 11 | 19.0 | 0 | 0.0 | 11 | 19.0 |
| Aspartate aminotransferase increased | 9 | 15.5 | 1 | 1.7 | 10 | 17.2 |
| GGT increased | 10 | 17.2 | 0 | 0.0 | 10 | 17.2 |
| Vomiting | 9 | 15.5 | 0 | 0.0 | 9 | 15.5 |
| Dyspnea | 9 | 15.5 | 0 | 0.0 | 9 | 15.5 |
| Cough | 9 | 15.5 | 0 | 0.0 | 9 | 15.5 |
| Alkaline phosphatase increased | 8 | 13.8 | 1 | 1.7 | 9 | 15.5 |
| Myalgia | 8 | 13.8 | 1 | 1.7 | 9 | 15.5 |
| Constipation | 8 | 13.8 | 0 | 0.0 | 8 | 13.8 |
| Thrombocytopenia | 7 | 12.1 | 1 | 1.7 | 8 | 13.8 |
| Dyspnea | 8 | 13.8 | 0 | 0.0 | 8 | 13.8 |
| Weight loss | 6 | 10.3 | 1 | 1.7 | 7 | 12.1 |
| Oral mucositis | 6 | 10.3 | 0 | 0.0 | 6 | 10.3 |
| Hyponatremia | 6 | 10.3 | 0 | 0.0 | 6 | 10.3 |
GGT, γ-glutamyltransferase.